vascular-targeting agent
A vascular-targeting agent (VTA) or vascular disrupting agent (VDA) is a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis.{{cite journal |url=http://clincancerres.aacrjournals.org/cgi/reprint/10/2/415.pdf |title=Vascular Targeting Agents as Cancer Therapeutics |year=2004 |doi=10.1158/1078-0432.CCR-0642-03 |last1=Thorpe |first1=Philip E. |journal=Clinical Cancer Research |volume=10 |issue=2 |pages=415–427 |pmid=14760060 |s2cid=1739027 }}
VTAs can be small-molecule or ligand-based.
Small-molecule VTAs include:
- microtubule destabilizing drugs such as combretastatin A-4 disodium phosphate (CA4P), ZD6126, AVE8062, Oxi 4503
- vadimezan (ASA404)
Clinical trials
Phase II : ZD6126, CA4P, plinabulin (NPI-2358){{cite web | title = NPI-2358 | url = http://clinicaltrials.gov/ct2/results?term=NPI-2358&Search=Search | publisher = clinicaltrials.gov}}{{Cite journal | title = Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas | author = Monica M. Mita| doi= 10.1158/1078-0432.CCR-10-1096 |journal = Clin Cancer Res | year = 2010 | volume = 16 | issue = 23 | pages = 5892–5899 | pmid=21138873|display-authors=etal| doi-access = free }}{{Cite journal
| title = Clinical Trials Update
| year = 2009
| author = Staff
| journal = Genetic Engineering & Biotechnology News
| pages = 58
| volume = 29
| issue = 8
}}
Phase III : DMXAA (ASA404).
References
{{Reflist}}
{{antineoplastic-drug-stub}}